Tag: NIH
-
NIH Funding Further Marburg Virus Therapy Development
BioCryst Pharmaceuticals Inc., a developer of drugs for infectious and rare diseases in Durham, North Carolina, says National Institutes of Health (NIH) is continuing its contract with the company to develop a treatment for Marburg virus, the cause of a rare but dangerous tropical disease. The contract extension, says BioCryst, is worth $2.5 million, increasing…
-
NIH Giving In-Kind Technical Services for Rare Diseases
National Institutes of Health (NIH) is supporting three new projects with technical research services for two companies and one university lab developing therapies for rare diseases. The projects aim to develop treatments for acute radiation syndrome, brain injury following cardiac arrest, and beta thalassemia, a rare blood disorder. The awards are a product of the…
-
Injectable Therapy for Rotator Cuff Injuries in Development
Biomedical engineers at Georgia Institute of Technology in Atlanta are developing a material to be injected into torn rotator cuff tendons, a common sports injury, to speed their healing. The five-year project is led by Georgia Tech’s biomedical engineering professor Johnna Temenoff and funded by a $1 million grant from National Institute of Arthritis and…
-
Neurotherapies Require Collaboration, Team Science, Big Data
In a briefing today on Capitol Hill, University of Pennsylvania biomedical engineer and neurologist Brian Litt outlined requirements for harnessing promising research for patients suffering from brain disorders. The briefing in Washington, D.C. was organized by the journal Science Translational Medicine and its publisher American Association for the Advancement of Science. Litt, who is on…
-
FDA Approves Sale of High-Throughput DNA Sequencing Systems
The U.S. Food and Drug Administration yesterday cleared for marketing high-throughput sequencing systems by Illumina Inc. in San Diego to analyze a person’s DNA. In a commentary on this approval in New England Journal of Medicine, FDA director Margaret Hamburg and National Institutes of Health director Francis Collins say, “Access to these data opens the…
-
Novartis Licenses University Stem Cell Transplant Technology
The global pharmaceutical company Novartis, based in Switzerland, is licensing research conducted at University of Louisville to help transplant patients better tolerate donated kidneys. Financial aspects of the agreement between Novartis and the Louisville biotechnology company Regenerex LLC, the original licensee and completed last month, were not disclosed. Regenerex is the company founded by Suzanne…
-
Many Large Clinical Trials Remain Unpublished
Medical researchers at University of North Carolina in Chapel Hill found some three in 10 clinical trials having 500 or more participants remain unpublished, with results from the vast majority of unpublished studies not made available on ClinicalTrials.gov, the U.S. government’s database. Findings from the team led by emergency medicine professor Timothy Platts-Mills were reported…
-
DNAnexus, Baylor Partner on Large-Scale Genomic Analysis
Genomics and bioinformatics researchers at Baylor College of Medicine in Houston and analytical services company DNAnexus in Mountain View, California are collaborating on large-scale genomic sequencing for research and clinical applications, with a cloud computing platform. The partnership already processed genomic data from more than 14,000 individuals for a genetics analysis on heart disease and…
-
Government Shut-Down Another Body Blow Say Life Scientists
The government shut-down, said a group of researchers, is taking a large and lasting toll on life sciences in the U.S., with the ripples being felt in the economy at large. The life scientists spoke today at a press conference in Washington, D.C. organized by American Society for Cell Biology (ASCB). The researchers, all from…
-
Challenge Seeks Commercialization of Breast Cancer Advances
A new challenge sponsored by the Avon Foundation for Women, with National Cancer Institute and Center for Advancing Innovation, aims to accelerate commercialization of unlicensed research discoveries related to breast cancer. In the Breast Cancer Start-up Challenge, Avon Foundation will award $250,000 to teams starting new companies that combine lab discoveries with solid business plans…